These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9067862)

  • 1. Insulin-like growth factor-I treatment reduces immune cell responses in acute non-demyelinative experimental autoimmune encephalomyelitis.
    Liu X; Linnington C; Webster HD; Lassmann S; Yao DL; Hudson LD; Wekerle H; Kreutzberg GW
    J Neurosci Res; 1997 Mar; 47(5):531-8. PubMed ID: 9067862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-like growth factor I treatment reduces clinical deficits and lesion severity in acute demyelinating experimental autoimmune encephalomyelitis.
    Liu X; Yao DL; Webster H
    Mult Scler; 1995 Apr; 1(1):2-9. PubMed ID: 9345463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like growth factor I treatment reduces demyelination and up-regulates gene expression of myelin-related proteins in experimental autoimmune encephalomyelitis.
    Yao DL; Liu X; Hudson LD; Webster HD
    Proc Natl Acad Sci U S A; 1995 Jun; 92(13):6190-4. PubMed ID: 7541143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor-I given subcutaneously reduces clinical deficits, decreases lesion severity and upregulates synthesis of myelin proteins in experimental autoimmune encephalomyelitis.
    Yao DL; Liu X; Hudson LD; Webster HD
    Life Sci; 1996; 58(16):1301-6. PubMed ID: 8614286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Astrocytes express insulin-like growth factor-I (IGF-I) and its binding protein, IGFBP-2, during demyelination induced by experimental autoimmune encephalomyelitis.
    Liu X; Yao DL; Bondy CA; Brenner M; Hudson LD; Zhou J; Webster HD
    Mol Cell Neurosci; 1994 Oct; 5(5):418-30. PubMed ID: 7529631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic relapsing experimental autoimmune encephalomyelitis: effects of insulin-like growth factor-I treatment on clinical deficits, lesion severity, glial responses, and blood brain barrier defects.
    Li W; Quigley L; Yao DL; Hudson LD; Brenner M; Zhang BJ; Brocke S; McFarland HF; Webster HD
    J Neuropathol Exp Neurol; 1998 May; 57(5):426-38. PubMed ID: 9596413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early pregnancy factor suppresses the infiltration of lymphocytes and macrophages in the spinal cord of rats during experimental autoimmune encephalomyelitis but has no effect on apoptosis.
    Athanasas-Platsis S; Zhang B; Hillyard NC; Cavanagh AC; Csurhes PA; Morton H; McCombe PA
    J Neurol Sci; 2003 Oct; 214(1-2):27-36. PubMed ID: 12972385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptosis of V beta 8.2+ T lymphocytes in the spinal cord during recovery from experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein.
    McCombe PA; Nickson I; Tabi Z; Pender MP
    J Neurol Sci; 1996 Jul; 139(1):1-6. PubMed ID: 8836965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats.
    Jung S; Zielasek J; Köllner G; Donhauser T; Toyka K; Hartung HP
    J Neuroimmunol; 1996 Aug; 68(1-2):1-11. PubMed ID: 8784254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulation of experimental autoimmune encephalomyelitis by staphylococcal enterotoxin D.
    Matsumoto Y; Fujiwara M
    Cell Immunol; 1993 Jul; 149(2):268-78. PubMed ID: 7687198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of experimental autoimmune encephalomyelitis in Lewis rats by nasal administration of encephalitogenic MBP peptides: synergistic effects of MBP 68-86 and 87-99.
    Liu JQ; Bai XF; Shi FD; Xiao BG; Li HL; Levi M; Mustafa M; Wahren B; Link H
    Int Immunol; 1998 Aug; 10(8):1139-48. PubMed ID: 9723700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Propentofylline and iloprost suppress the production of TNF-alpha by macrophages but fail to ameliorate experimental autoimmune encephalomyelitis in Lewis rats.
    Jung S; Donhauser T; Toyka KV; Hartung HP
    J Autoimmun; 1997 Dec; 10(6):519-29. PubMed ID: 9451591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-beta mRNA.
    Bai XF; Shi FD; Xiao BG; Li HL; van der Meide PH; Link H
    J Neuroimmunol; 1997 Dec; 80(1-2):65-75. PubMed ID: 9413260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corticosteroid treatment of experimental autoimmune encephalomyelitis in the Lewis rat results in loss of V beta 8.2+ and myelin basic protein-reactive cells from the spinal cord, with increased total T-cell apoptosis but reduced apoptosis of V beta 8.2+ cells.
    McCombe PA; Nickson I; Tabi Z; Pender MP
    J Neuroimmunol; 1996 Nov; 70(2):93-101. PubMed ID: 8898717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of DAB(389)IL-2 immunotoxin on the course of experimental autoimmune encephalomyelitis in Lewis rats.
    Phillips SM; Bhopale MK; Constantinescu CS; Ciric B; Hilliard B; Ventura E; Lavi E; Rostami A
    J Neurol Sci; 2007 Dec; 263(1-2):59-69. PubMed ID: 17603081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The inflammatory lesion of T cell line transferred experimental autoimmune encephalomyelitis of the Lewis rat: distinct nature of parenchymal and perivascular infiltrates.
    Lannes-Vieira J; Gehrmann J; Kreutzberg GW; Wekerle H
    Acta Neuropathol; 1994; 87(5):435-42. PubMed ID: 7520206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of timing of intravenous administration of myelin basic protein on the induction of tolerance in experimental allergic encephalomyelitis.
    Hilliard B; Ventura ES; Rostami A
    Mult Scler; 1999 Feb; 5(1):2-9. PubMed ID: 10096096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis.
    Aikawa Y; Tanuma N; Shin T; Makino S; Tanaka K; Matsumoto Y
    J Neuroimmunol; 1998 Aug; 89(1-2):35-42. PubMed ID: 9726823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell receptor (TCR) usage in Lewis rat experimental autoimmune encephalomyelitis: TCR beta-chain-variable-region V beta 8.2-positive T cells are not essential for induction and course of disease.
    Gold R; Giegerich G; Hartung HP; Toyka KV
    Proc Natl Acad Sci U S A; 1995 Jun; 92(13):5850-4. PubMed ID: 7597040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dependent mechanisms relate to nasal tolerance induction and protection against experimental autoimmune encephalomyelitis in Lewis rats.
    Li HL; Liu JQ; Bai XF; vn der Meide PH; Link H
    Immunology; 1998 Jul; 94(3):431-7. PubMed ID: 9767428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.